Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Trend | Peers | Company |
|---|---|---|
| Is return on equity increasing? | Yes | No |
| Is net profit margin increasing? | Yes | Yes |
| Is asset turnover increasing? | Yes | No |
| Is equity multiplier increasing? | Yes | Yes |
| Competitors Used |
|---|
| Exact Sciences Corporation |
| GRAIL, Inc. |
| Sangui Biotech International, Inc. |
| Tango Therapeutics, Inc. |
| argenx SE |
| Return on Equity Benchmarks | ||||||||
| Comparable Companies | ||||||||
| EXAS | GRAL | SGBI | TNGX | ARGN.F | MYNZ | |||
| Return On Equity | ||||||||
| Latest Twelve Months | -37% | -66% | -40% | -58% | 17% | -466% | ||
| Fiscal Year - 1 | -7% | -35% | 48% | -40% | -9% | -303% | ||
| Fiscal Year - 2 | -19% | -77% | 26% | -36% | -27% | -258% | ||
| Fiscal Year - 3 | -21% | -31% | 130% | -30% | -19% | -646% | ||
| Fiscal Year - 4 | -36% | NA | NM | NM | -43% | 21% | ||
| Fiscal Year - 5 | -14% | NA | -202% | 29% | -20% | NA | ||
| Average | -23% | -52% | -8% | -27% | -17% | -330% | ||
| Median | -20% | -51% | 26% | -36% | -20% | -303% | ||
| Benchmarks | Ticker | |||||||
| Exact Sciences Corporation | NasdaqCM:EXAS | |||||||
| GRAIL, Inc. | NasdaqGS:GRAL | |||||||
| Sangui Biotech International, Inc. | OTCPK:SGBI | |||||||
| Tango Therapeutics, Inc. | NasdaqGM:TNGX | |||||||
| argenx SE | OTCPK:ARGN.F | |||||||
| Financial Performance | ||||||||
| Comparable Companies | ||||||||
| (in millions) | EXAS | GRAL | SGBI | TNGX | ARGN.F | MYNZ | ||
| Latest Fiscal Year | Dec-24 | Dec-24 | Jun-24 | Dec-24 | Dec-24 | Dec-24 | ||
| LTM Period | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
| Revenues | ||||||||
| Latest Twelve Months | 2,759 | 126 | 0 | 42 | 2,248 | 1 | ||
| Fiscal Year | 2,759 | 126 | 0 | 42 | 2,248 | 1 | ||
| Fiscal Year - 1 | 2,500 | 93 | 0 | 37 | 1,269 | 1 | ||
| Fiscal Year - 2 | 2,084 | 56 | 0 | 25 | 441 | 1 | ||
| Fiscal Year - 3 | 1,767 | 15 | 0 | 37 | 528 | 1 | ||
| Fiscal Year - 4 | 1,491 | NA | 0 | 8 | 62 | 0 | ||
| Fiscal Year - 5 | 876 | NA | 0 | 25 | 93 | 0 | ||
| Net Income | ||||||||
| Latest Twelve Months | (1,029) | (2,027) | 0 | (130) | 833 | (22) | ||
| Fiscal Year | (1,029) | (2,027) | (0) | (130) | 833 | (22) | ||
| Fiscal Year - 1 | (204) | (1,466) | (0) | (102) | (295) | (26) | ||
| Fiscal Year - 2 | (624) | (5,399) | (0) | (108) | (710) | (26) | ||
| Fiscal Year - 3 | (596) | (1,248) | (0) | (58) | (408) | (12) | ||
| Fiscal Year - 4 | (824) | (312) | (0) | (52) | (608) | (1) | ||
| Fiscal Year - 5 | (213) | (245) | (0) | (14) | (181) | (1) | ||
| Total Assets | ||||||||
| Latest Fiscal Quarter Prior | 6,471 | 3,914 | 0 | 403 | 4,542 | 15 | ||
| Latest Fiscal Quarter | 5,928 | 2,983 | 0 | 316 | 6,203 | 13 | ||
| Fiscal Year | 5,928 | 2,983 | 0 | 316 | 6,203 | 13 | ||
| Fiscal Year - 1 | 6,471 | 3,914 | 0 | 403 | 4,542 | 15 | ||
| Fiscal Year - 2 | 6,227 | 4,938 | 0 | 436 | 3,134 | 20 | ||
| Fiscal Year - 3 | 6,685 | 9,738 | 0 | 500 | 2,850 | 10 | ||
| Fiscal Year - 4 | 4,925 | 706 | 0 | 207 | 2,279 | 1 | ||
| Fiscal Year - 5 | 3,506 | 636 | 0 | 56 | 1,610 | NA | ||
| Fiscal Year - 6 | 1,524 | 687 | 0 | NA | 663 | NA | ||
| Common Equity | ||||||||
| Latest Fiscal Quarter Prior | 3,145 | 3,646 | (0) | 253 | 4,098 | 3 | ||
| Latest Fiscal Quarter | 2,402 | 2,503 | (0) | 200 | 5,498 | 6 | ||
| Fiscal Year | 2,402 | 2,503 | (0) | 200 | 5,498 | 6 | ||
| Fiscal Year - 1 | 3,145 | 3,646 | (0) | 253 | 4,098 | 3 | ||
| Fiscal Year - 2 | 3,043 | 4,646 | (0) | 249 | 2,814 | 14 | ||
| Fiscal Year - 3 | 3,388 | 9,431 | (0) | 345 | 2,534 | 6 | ||
| Fiscal Year - 4 | 2,236 | (1,433) | (0) | 39 | 1,674 | (3) | ||
| Fiscal Year - 5 | 2,288 | (1,213) | 0 | (48) | 1,180 | NA | ||
| Fiscal Year - 6 | 681 | (1,003) | 0 | NA | 617 | NA | ||